ReviewLeukemia2006
Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.
Review in Leukemia, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01828619 (The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases), which is not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases
Who cites it
42 citing papers in PubMed, 125 citations in OpenAlex.
- Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma.Bone marrow transplantation · 2012Trial
- Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?Bone marrow transplantation · 2008Trial
- Retarded DNA DSB repair kinetics and augmented radiation sensitivity in Wiskott Aldrich syndrome patients.Scientific reports · 2026Article
- Oral microbial changes and oral disease management before and after the treatment of hematological malignancies: a narrative review.Clinical oral investigations · 2023Review
- Prophylactic or pre-emptive therapies to prevent relapse after allogeneic hematopoietic stem cell transplantation.International journal of hematology · 2023Article
- Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.International journal of hematology · 2022Article
- Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens.Bone marrow transplantation · 2020Article
- Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.Blood advances · 2020Article
- Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.Blood advances · 2019Article
- Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country.Bone marrow transplantation · 2019Article
- Article
- The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.Blood reviews · 2017Review
- Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia.Current oncology (Toronto, Ont.) · 2017Article
- Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Frontiers in immunology · 2017Review
- Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML.Bone marrow transplantation · 2016Article
- Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Article
- I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.Bone marrow transplantation · 2015Article
- Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.Bone marrow transplantation · 2015Review
- Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014Article
- Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Bone marrow transplantation · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The realization in the 1990s that allogeneic stem cell transplants (SCT) have a potentially curative graft-versus-leukemia (GVL) effect in addition to the antileukemic action of myeloablative conditioning regimens was a major stimulus for the development of reduced-intensity conditioning (RIC) regimens, aimed primarily at securing engraftment to provide the GVL effect, while minimizing regimen-related toxicity. It is now over 10 years since RIC regimens were heralded as a new direction in the field of SCT. Over the last decade much has been learned about the ways in which the conditioning regimen can be tailored to provide adequate immunosuppression, and modulated to deliver a chosen degree of antimalignant treatment. The huge literature of clinical data with RIC transplantation now permits us to more clearly define the success and limitations of the approach. This review examines the origins of RIC SCT, explores the degree to which the initial expectations and purpose of the approach have been realized, and outlines some ways forward for the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.